Skip to main content
European Commission logo print header

taRgeted thErapy for adVanced colorEctal canceR paTients

Descrizione del progetto

Modello di medicina personalizzata per il trattamento del tumore del colon-retto avanzato

Il progetto REVERT, finanziato dall’UE, affronterà a livello di sistemi la patofisiologia del tumore del colon-retto avanzato nei pazienti che rispondono bene o scarsamente alle terapie, con l’obiettivo di progettare una strategia ottimale per interventi terapeutici in base alle caratteristiche dei pazienti. Questo obiettivo sarà raggiunto utilizzando un gran numero di campioni standardizzati di biobanche e banche dati cliniche provenienti da numerosi centri clinici europei, inclusi biomarcatori prognostici noti e potenzialmente nuovi. A seguito dell’analisi dei dati basata sull’intelligenza artificiale, i risultati saranno valutati per l’impatto del database di REVERT sulla sopravvivenza e sulla qualità della vita in future sperimentazioni cliniche. Il progetto genererà anche un’ampia rete di partner industriali e accademici focalizzata sullo sviluppo della medicina personalizzata.

Obiettivo

The REVERT project will address the specific challenge of understanding at system level the pathophysiology of mCRC cancer in patients responding well or poorly to therapies, in order to design optimal strategy for mCRC on a case by case basis, with therapeutic interventions modulated depending on patient’s features. Accordingly, REVERT will build up an innovative artificial intelligence (AI)-based decision support system using the experience and the real-world data of several general Hospitals operating in the EU healthcare system ultimately aimed at developing an improved and innovative model of combinatorial therapy - based on a personalised medicine approach - that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC. This goal will be pursued through the building of the REVERT-DataBase (RDB) thanks to a large number of standardized biobank samples with related structured data, and clinical databases (including known clinical and biological features as well as new, potential prognostic/predictive biomarkers) from several major clinical European centres. The RDB, in turn, will be used to build a sophisticated computational framework based on AI to evaluate its impact on survival and quality of life in a prospective clinical trial through testing of new treatment sequences of the available and authorised molecular targeted drugs in patients with mCRC. In the end, the REVERT will also generate an EU- network among SMEs, Research Institutions, Clinical Centres and Biobanks focused on R&D in the field of AI-Health for the development of personalised medicine.
The REVERT software system will ensure the integrity of data and privacy management in respect to national rules, the EU's GDPR (Reg. EU 2016/679) and the EU Charter of Fundamental Rights. The RDB and AI services will be open to all partners during and after project’s completion, available also to EU research Institutions for future studies.

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2019-Two-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

IRCCS SAN RAFFAELE ROMA SRL
Contribution nette de l'UE
€ 998 125,00
Indirizzo
VIA DELLA PISANA 235
00163 Roma Rm
Italia

Mostra sulla mappa

Regione
Centro (IT) Lazio Roma
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 998 125,00

Partecipanti (22)